Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00671723 · ClinicalTrials.gov registry record · NA
Dornase Alpha Versus Hypertonic Saline for Lung Atelectasis in Non-Cystic Fibrosis Patients
A NA study, sponsored by University of Oklahoma.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
NCT00671723 is a NA study that has completed, run by University of Oklahoma. The registered enrollment target is 33 participants.
The verdict
NCT00671723, a NA study, has completed, sponsored by University of Oklahoma.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
Study Summary
Despite the lack of trials proving the efficacy of DNase in non cystic fibrosis patients, it is currently heavily used in this population. In fact, per evidence of barcode scanning via Meditech computer system at OU Medical Center 93% of the DNase prescribed in 2005 was for non Cystic fibrosis patients with an estimated yearly cost of $341,968.15.In vitro studies showed that the effect of Dnase was minimal on sputum viscosity when compared to Hypertonic saline . Furthermore recent studies on hypertonic saline in cystic fibrosis patients showed that it is an inexpensive and safe therapy when preceded by a bronchodilator in patients with cystic fibrosis. We hereby propose a prospective randomized trial to compare the efficacy of hypertonic saline, DNase, vs. normal saline in the treatment of atelectasis in non cystic fibrosis, mechanically ventilated patient.
Interventions
- DRUG Hypertonic Saline
- DRUG Normal saline:
- DRUG Dornase alpha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2006-10 |
| Est. Completion | 2008-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00671723
The ClinicalTrials.gov registry entry for NCT00671723 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Hypertonic Saline is the first listed.
NCT00671723 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00671723 about?
NCT00671723 is a clinical study titled "Dornase Alpha Versus Hypertonic Saline for Lung Atelectasis in Non-Cystic Fibrosis Patients". Despite the lack of trials proving the efficacy of DNase in non cystic fibrosis patients, it is currently heavily used in this population. In fact, per evidence of barcode scanning via Meditech computer system at OU Medical Center 93% of the DNase prescribed in 2005 was for non Cystic fibrosis patie...
What is the current status of trial NCT00671723?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2006-10. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00671723?
The interventions under investigation include: Hypertonic Saline (DRUG), Normal saline: (DRUG), Dornase alpha (DRUG).
Who is sponsoring clinical trial NCT00671723?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.